THDB(600867)2025-01-20 08:50Financial Performance - The company expects a net profit attributable to shareholders of approximately 40.53 million yuan for the year 2024, a decrease of about 112.73 million yuan, representing a year-on-year decline of approximately 96.53%[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be around 270.72 million yuan, a decrease of about 89.68 million yuan, which is a year-on-year decline of approximately 76.81%[5] - In 2023, the total profit was 1.37 billion yuan, with a net profit attributable to shareholders of 1.17 billion yuan[7] Project Termination and Impairment - The company decided to terminate the clinical research and development of the BioChaperone® Combo project, resulting in a full impairment of 64.56 million yuan and a loss recognition of 253.52 million yuan related to commercialization rights[10] - The termination of the THDB0207 injection project will reduce the company's net profit for 2024 by 270.37 million yuan and decrease non-recurring gains and losses by 215.50 million yuan[10] Sales Revenue Decline - The decline in sales revenue is attributed to the implementation of a new round of insulin procurement, which led to a decrease in the bidding prices of insulin products[9] Earnings Forecast - The company has not identified any uncertainties that would affect the accuracy of this earnings forecast[11] - The earnings forecast is based on preliminary calculations by the company's finance department and has not been audited by registered accountants[11] - The data provided in the earnings forecast is preliminary and the final financial data will be disclosed in the official 2024 annual report[12] - The company emphasizes the importance of investors being aware of investment risks related to the preliminary earnings forecast[12]